These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 37302149)
21. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH; Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257 [TBL] [Abstract][Full Text] [Related]
22. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492 [TBL] [Abstract][Full Text] [Related]
23. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508 [TBL] [Abstract][Full Text] [Related]
34. Ticagrelor as Compared to Clopidogrel Following Percutaneous Coronary Intervention for Acute Coronary Syndrome. Wiens EJ; Leon SJ; Whitlock R; Tangri N; Shah AH Am J Cardiol; 2023 Jul; 198():26-32. PubMed ID: 37196530 [TBL] [Abstract][Full Text] [Related]
35. Ischemic and Bleeding Outcomes of Potent P2Y12 Inhibitor Antiplatelet Agents Versus Clopidogrel in Elderly Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials. Abusnina W; Al-Abdouh A; Bizanti A; Gill G; Houssien A; Alshebani Y; Kanmanthareddy A; Dahal K Cardiovasc Revasc Med; 2022 May; 38():54-60. PubMed ID: 34384690 [TBL] [Abstract][Full Text] [Related]
36. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome. Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388 [TBL] [Abstract][Full Text] [Related]
37. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798 [TBL] [Abstract][Full Text] [Related]
38. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475 [TBL] [Abstract][Full Text] [Related]
39. Safety and Effectiveness of Contemporary P2Y Yun JE; Kim YJ; Park JJ; Kim S; Park K; Cho MS; Nam GB; Park DW J Am Heart Assoc; 2019 Jul; 8(14):e012078. PubMed ID: 31310570 [TBL] [Abstract][Full Text] [Related]
40. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Bavishi C; Panwar S; Messerli FH; Bangalore S Am J Cardiol; 2015 Sep; 116(5):809-17. PubMed ID: 26119655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]